EA201100032A1 - Соединения пиридина - Google Patents

Соединения пиридина

Info

Publication number
EA201100032A1
EA201100032A1 EA201100032A EA201100032A EA201100032A1 EA 201100032 A1 EA201100032 A1 EA 201100032A1 EA 201100032 A EA201100032 A EA 201100032A EA 201100032 A EA201100032 A EA 201100032A EA 201100032 A1 EA201100032 A1 EA 201100032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridine compounds
medicines
preparation
compounds
cancer
Prior art date
Application number
EA201100032A
Other languages
English (en)
Other versions
EA020807B1 (ru
Inventor
Бернар Кристоф Барлам
Кевин Майкл Фут
Патрик Пле
Клиффорд Дейвид Джонс
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201100032A1 publication Critical patent/EA201100032A1/ru
Publication of EA020807B1 publication Critical patent/EA020807B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям, которые ингибируют функцию киназы фокальной адгезии, способам их получения, фармацевтическим композициям, содержащим их в качестве активного ингредиента, к их применению в качестве лекарственных средств и к их применению для приготовления лекарственных средств для применения при лечении у теплокровных животных, таких как люди, заболеваний, таких как рак.
EA201100032A 2008-06-17 2009-06-15 Соединения пиридина EA020807B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17
PCT/GB2009/050675 WO2009153589A1 (en) 2008-06-17 2009-06-15 Pyridine compounds

Publications (2)

Publication Number Publication Date
EA201100032A1 true EA201100032A1 (ru) 2012-01-30
EA020807B1 EA020807B1 (ru) 2015-01-30

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100032A EA020807B1 (ru) 2008-06-17 2009-06-15 Соединения пиридина

Country Status (18)

Country Link
US (1) US8569298B2 (ru)
EP (1) EP2303861B1 (ru)
JP (1) JP5551689B2 (ru)
KR (1) KR101695501B1 (ru)
CN (1) CN102124000B (ru)
AU (1) AU2009261764B2 (ru)
BR (1) BRPI0914927B8 (ru)
CA (1) CA2726508C (ru)
CR (1) CR11854A (ru)
DO (1) DOP2010000390A (ru)
EA (1) EA020807B1 (ru)
EC (1) ECSP10010695A (ru)
ES (1) ES2472323T3 (ru)
HK (1) HK1155170A1 (ru)
IL (1) IL209727A0 (ru)
MX (1) MX2010014057A (ru)
WO (1) WO2009153589A1 (ru)
ZA (1) ZA201100388B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
WO2011014462A1 (en) 2009-07-27 2011-02-03 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
JP5936609B2 (ja) 2010-06-29 2016-06-22 ベラステム インコーポレイテッド キナーゼインヒビターの経口製剤
MX343894B (es) 2010-06-30 2016-11-28 Poniard Pharmaceuticals Inc * Síntesis y uso de inhibidores de cinasa.
WO2012003392A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2667871A4 (en) * 2011-01-26 2014-07-09 Glaxosmithkline Intellectual Property Ltd SUITS
CN103534241B (zh) 2011-02-17 2015-11-25 癌症疗法Crc私人有限公司 Fak抑制剂
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (ru) 2011-07-01 2018-04-28
CA2867467A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
RS58632B1 (sr) * 2014-06-17 2019-05-31 Pfizer Supstituisana jedinjenja dihidroizohinolinona
US9442005B2 (en) * 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
SG11201705088VA (en) 2014-12-23 2017-07-28 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
WO2017004192A1 (en) 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
MX2020009023A (es) 2018-02-28 2020-10-12 Basf Se Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificacion.
CN111683528B (zh) 2018-02-28 2022-12-13 巴斯夫欧洲公司 吡唑炔丙基醚作为硝化抑制剂的用途
RU2020133451A (ru) 2018-03-12 2022-04-12 Инститьют Насьонал Де Ла Санте Et De La Решерш Медикаль (Инсерм) Применение терапевтически эффективной комбинации химиотерапиии и ингибитора контрольной точки иммунного ответа с миметиком ограничения калорийности для лечения рака
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
AU2020365108A1 (en) * 2019-10-18 2022-04-21 Atengen, Inc. 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
CA3219128A1 (en) 2021-05-21 2022-11-24 Barbara Nave Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
WO2005016894A1 (en) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA06015170A (es) 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1966207A2 (en) 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
ME00811B (me) 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
JP5569956B2 (ja) * 2007-03-16 2014-08-13 ザ スクリプス リサーチ インスティテュート 接着斑キナーゼのインヒビター
JP2010533729A (ja) * 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
EP2249650A4 (en) * 2008-02-19 2012-01-11 Glaxosmithkline Llc ANILINOPYRIDINE AS A FAK HEMMER

Also Published As

Publication number Publication date
EP2303861A1 (en) 2011-04-06
WO2009153589A1 (en) 2009-12-23
BRPI0914927A2 (pt) 2017-06-20
CN102124000B (zh) 2014-09-17
US20110166139A1 (en) 2011-07-07
AU2009261764A1 (en) 2009-12-23
ZA201100388B (en) 2011-10-26
DOP2010000390A (es) 2011-01-15
BRPI0914927B1 (pt) 2020-10-06
KR20110023884A (ko) 2011-03-08
EP2303861B1 (en) 2014-04-23
BRPI0914927B8 (pt) 2021-05-25
CA2726508A1 (en) 2009-12-23
AU2009261764B2 (en) 2013-01-10
HK1155170A1 (en) 2012-05-11
EA020807B1 (ru) 2015-01-30
IL209727A0 (en) 2011-02-28
US8569298B2 (en) 2013-10-29
KR101695501B1 (ko) 2017-01-11
JP2011524411A (ja) 2011-09-01
JP5551689B2 (ja) 2014-07-16
ES2472323T3 (es) 2014-06-30
CA2726508C (en) 2016-06-07
CR11854A (es) 2011-02-25
CN102124000A (zh) 2011-07-13
MX2010014057A (es) 2011-03-21
ECSP10010695A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
EA201100032A1 (ru) Соединения пиридина
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
EA202090662A3 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BRPI0915084B8 (pt) composto, e, composição farmacêutica
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM